Atropine (opthimalic use)

Uses & side effects

In valid veterinary medicine, atropine acts as a powerful mydriatic (pupil dilator) and cycloplegic (ciliary muscle paralyzer). By temporarily relaxing the spasming muscles within an inflamed eye, it alleviates severe ocular pain, stabilizes the blood-aqueous barrier, and prevents blinding complications like posterior synechiae (where the iris permanently adheres to the lens).2. Methods of Abuse in Horse CompetitionsDespite its medical importance, atropine has a long history of illicit use or "abuse" in performance environments. Unscrupulous trainers manipulate its physiological effects for two primary competitive advantages:Masking Visual Deficits: If a horse has suffered a past eye injury, chronic uveitis, or early cataracts, its pupils may remain uneven, constricted, or noticeably cloudy. This asymmetry can cause judges to penalize the horse for a lack of structural soundness or alert expression. Trainers have used unilateral (one-sided) atropine drops to manually force a constricted pupil to dilate, artificially matching the healthy eye to fool pre-purchase examiners or show ring judges.Behavioral Modification (Unintended Sedation): Atropine is an anticholinergic agent. When applied topically, it rapidly drains through the nasolacrimal duct into the nasal passages and is absorbed systemically into the bloodstream. At high or frequent doses, its systemic block of acetylcholine receptors can induce a mild, lethargic, or unnaturally calm mental state in a high-strung horse. This calming effect is chemically exploited to achieve a quiet, rhythmic performance in judged classes like hunters or dressage.

Product-specific side effects await source review.

Drug interactions

Equine uveitis is a leading cause of blindness in horses [1–3]. Uveitis may cause ciliary muscle spasm as well as pupillary contraction (miosis). The spasm is painful and chronic complications may occur, including synechia between tissues in the eye that can cause persistent pupil constriction, glaucoma and decreased vision. Topical ophthalmic administration of the non-selective muscarinic receptor-antagonist atropine sulfate induce cycloplegia, which alleviates the painful spasm caused by uveitis. Atropine also induces mydriasis, which is beneficial to minimize the risk for the development of synechia. Synechia can obstruct aqueous humor outflow and thus cause secondary glaucoma, as well as cause reduced vision and blindness through persistent pupil constriction [4, 5]. Atropine has also been shown to stabilize the blood-aqueous barrier, and thereby reduce the leakage of detrimental inflammatory cells and debris into the aqueous chamber [6]. Thus, atropine is an important part of the treatment protocol in equine uveitis [7, 8]. Unfortunately, intestinal motility is also mediated by muscarinic receptors, and systemic atropine exposure has been shown to decrease borborygmi-frequency, increase intestinal transit time, and has also been associated with colic in horses [6, 9–15]. After topical administration of 1 mg atropine sulfate every hour in the conjunctival sac, intestinal motility decreased and clinical signs of abdominal pain developed in 4/6 horses [16]. The onset of these adverse effects was between 11 h and 22 h after the first administered dose. In contrast, 1 mg of topical ophthalmic atropine sulfate every six hours did not affect intestinal transit time or borborygmi-frequency, nor cause signs of colic or abdominal discomfort in another study in six horses [17]. These conflicting results suggest that the systemic atropine exposure after the less frequent dosing-protocol was not associated with a decrease in intestinal motility. This hypothesis was also supported by non-detectable plasma concentrations of atropine six hours after topical administration of 1 mg atropine sulfate, which was the first sampling time post administration [17]. However, the systemic disposition of atropine in horses following different modalities of atropine administration including topical eye medication is currently not reported in horses. The aims of this study was to characterize, to model, and to simulate the pharmacokinetics of atropine in horses. A second aim was to investigate the borborygmi-frequency response to 1 mg atropine sulfate administered topically following different dosing regimens. The third aim was to relate the simulated atropine plasma concentration-time courses to the gastrointestinal motility response and development of signs of colic. Atropine is considered performance enhancing because it enables horses to take in more air in their lungs. Atropine acts as a performance-enhancing agent in horses primarily because of its powerful bronchodilating (airway-opening) and anticholinergic properties. By blocking the nervous system's parasympathetic responses, it can temporarily mask breathing issues like equine asthma (heaves) and increase heart rate.Key Performance-Enhancing EffectsMaximum Bronchodilation: Atropine prevents the neurotransmitter acetylcholine from binding to receptors in the airway's smooth muscle. This rapidly opens airways, allowing the horse to take in more oxygen during extreme exertion, which is highly beneficial in racehorses or performance horses with compromised respiratory function.Increased Heart Rate: By blocking the vagus nerve (which normally slows heart rate), atropine causes an immediate elevation in heart rate and cardiac output. In certain sports, this can be manipulated to achieve higher output, though it drastically increases the risk of dangerous arrhythmias.Pain Masking: Historically, it can also decrease intestinal spasms (pain from colic), potentially allowing a horse to compete even when injured or physically distressed.The Risks and RegulationsWhile it provides a temporary athletic edge, atropine carries severe side effects and is highly regulated or completely banned by equestrian authorities.Side Effects: It can cause dangerously dry mucous membranes, blurred vision, and severely slowed gut motility, which can lead to life-threatening colic or ileus.Doping Rules: Because of its potential to artificially enhance oxygen intake, mask distress, and dangerously alter cardiovascular function, it is listed as a prohibited or controlled substance in professional horse racing and equestrian sports.

Contraindications